These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 9796961

  • 1. Phase I trial of cremophor EL with bolus doxorubicin.
    Millward MJ, Webster LK, Rischin D, Stokes KH, Toner GC, Bishop JF, Olver IN, Linahan BM, Linsenmeyer ME, Woodcock DM.
    Clin Cancer Res; 1998 Oct; 4(10):2321-9. PubMed ID: 9796961
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Paclitaxel and pegylated liposomal doxorubicin in recurrent head and neck cancer: clinical and unexpected pharmacokinetic interactions.
    Airoldi M, Cattel L, Milla P, Pedani F, Garzaro M, Dosio F.
    Anticancer Res; 2008 Oct; 28(4C):2519-27. PubMed ID: 18751444
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer.
    D'Andrea G, Fennelly D, Norton L, Baselga J, Gilewski T, Hudis C, Moynahan ME, Raptis G, Sklarin N, Surbone A, Theodoulou M, Templeton MA, Yao TJ, Seidman AD.
    Clin Cancer Res; 1999 Feb; 5(2):275-9. PubMed ID: 10037175
    [Abstract] [Full Text] [Related]

  • 8. Phase I and pharmacologic study of a 3-hour infusion of paclitaxel followed by cisplatinum and 5-fluorouracil in patients with advanced solid tumors.
    Bhalla KN, Kumar GN, Walle UK, Ibrado AM, Javed T, Stuart RK, Reed C, Arbuck SG, Walle T.
    Clin Cancer Res; 1999 Jul; 5(7):1723-30. PubMed ID: 10430075
    [Abstract] [Full Text] [Related]

  • 9. [Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients].
    Wihlm J, Limacher JM, Levêque D, Duclos B, Dufour P, Bergerat JP, Methlin G.
    Bull Cancer; 1997 Jun; 84(6):603-8. PubMed ID: 9295863
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.
    Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, Esmaeli B, Ring SE, Bedikian A, Hortobagyi GN, Ellerhorst JA.
    Clin Cancer Res; 2002 May; 8(5):1038-44. PubMed ID: 12006516
    [Abstract] [Full Text] [Related]

  • 13. A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.
    van den Bongard HJ, Mathôt RA, van Tellingen O, Schellens JH, Beijnen JH.
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):16-24. PubMed ID: 12111107
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.
    Malingré MM, Schellens JH, Van Tellingen O, Ouwehand M, Bardelmeijer HA, Rosing H, Koopman FJ, Schot ME, Ten Bokkel Huinink WW, Beijnen JH.
    Br J Cancer; 2001 Nov 16; 85(10):1472-7. PubMed ID: 11720431
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors.
    Tranchand B, Catimel G, Lucas C, Sarkany M, Bastian G, Evene E, Guastalla JP, Négrier S, Rebattu P, Dumortier A, Foy M, Grossin F, Mazier B, Froudarakis M, Barbet N, Clavel M, Ardiet C.
    Cancer Chemother Pharmacol; 1998 Nov 16; 41(4):281-91. PubMed ID: 9488597
    [Abstract] [Full Text] [Related]

  • 18. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K, Frye D, Newman RA, Walters R, Theriault R, Fraschini G, Smith T, Buzdar A, Hortobagyi GN.
    Clin Cancer Res; 1995 Jul 16; 1(7):691-7. PubMed ID: 9816034
    [Abstract] [Full Text] [Related]

  • 19. A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study.
    Fokkema E, Verweij J, van Oosterom AT, Uges DR, Spinelli R, Valota O, de Vries EG, Groen HJ.
    Br J Cancer; 2000 Feb 16; 82(4):767-71. PubMed ID: 10732743
    [Abstract] [Full Text] [Related]

  • 20. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients.
    van Tellingen O, Huizing MT, Panday VR, Schellens JH, Nooijen WJ, Beijnen JH.
    Br J Cancer; 1999 Sep 16; 81(2):330-5. PubMed ID: 10496361
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.